DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting April 19, 2016 • 9:10 AM EDT
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083 April 19, 2016 • 9:00 AM EDT
DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer April 18, 2016 • 9:00 AM EDT
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016 March 24, 2016 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update February 16, 2016 • 7:35 AM EST
DelMar Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 February 4, 2016 • 7:35 AM EST
DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer January 13, 2016 • 8:05 AM EST
DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016 January 5, 2016 • 7:00 AM EST